BFM
BDTX icon

Boothbay Fund Management’s Black Diamond Therapeutics BDTX Stock Holding History

Boothbay Fund Management’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-141,347
Closed -$397K – 1594
2023
Q4 		$397K Buy
141,347
+21,585
+18% +$50.6K 0.01% 1079
2023
Q3 		$344K Buy
119,762
+10,469
+10% +$38.6K 0.01% 1198
2023
Q2 		$552K Buy
+109,293
New +$223K 0.01% 1047
2022
Q2 		– Sell
-14,931
Closed -$41K – 2256
2022
Q1 		$41K Hold
14,931
– – ﹤0.01% 2194
2021
Q4 		$80K Hold
14,931
– – ﹤0.01% 1738
2021
Q3 		$126K Sell
14,931
-6,353
-30% -$62.7K ﹤0.01% 1752
2021
Q2 		$259K Buy
21,284
+1,835
+9% +$36.3K 0.01% 1373
2021
Q1 		$472K Sell
19,449
-17,312
-47% -$467K 0.02% 976
2020
Q4 		$1.18M Sell
36,761
-6,113
-14% -$201K 0.04% 442
2020
Q3 		$1.3M Buy
42,874
+20,846
+95% +$634K 0.08% 351
2020
Q2 		$929K Buy
+22,028
New +$811K 0.06% 411

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Boothbay Fund Management's BDTX Position: Q1 2024 in Review

Boothbay Fund Management sold out of Black Diamond Therapeutics (BDTX) in Q1 2024, closing a stake of 141,347 shares — an estimated $397K sold.

Boothbay Fund Management first reported a position in BDTX in Q2 2020 and held it in 11 quarters. The position peaked at $1.3M in Q3 2020. 88 funds tracked by Wall St. Rank hold BDTX as of Q1 2024.

  • Boothbay Fund Management reported no remaining Black Diamond Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Boothbay Fund Management sold 141,347 Black Diamond Therapeutics shares in Q1 2024, an estimated $397K.
  • Boothbay Fund Management first reported a position in Black Diamond Therapeutics in Q2 2020 and held it in 11 quarters.
  • Boothbay Fund Management's Black Diamond Therapeutics position peaked at $1.3M in Q3 2020.
  • 88 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2024.

Based on Boothbay Fund Management's 13F filing for Q1 2024, filed 15 May 2024.